Manufacturer
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG
Contents
Dabigatran etexilate
Indication
75-mg & 110-mg cap: Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip or knee replacement surgery (pVTEp). 110-mg & 150-mg cap: Reduction of the risk of stroke & systemic embolism in patients w/ non-valvular atrial fibrillation (SPAF). Deep vein thrombosis (DVT) & pulmonary embolism (PE), prevention of recurrent DVT & PE in adults.
Instruction
May be taken with or without food: Swallow whole, do not chew/crush.
Drug interaction
Increased risk of bleeding w/ drugs that act on haemostatis or coagulation. Increased plasma conc w/ P-gp inhibitors eg, amiodarone, verapamil, quinidine, systemic ketoconazole, dronedarone, ticagrelor & clarithromycin. Reduced exposure w/ P-gp inducers eg, rifampicin.
Malaysia
